EQL Pharma Inkomsten in het verleden
Verleden criteriumcontroles 1/6
EQL Pharma has been growing earnings at an average annual rate of 35.3%, while the Healthcare industry saw earnings growing at 20% annually. Revenues have been growing at an average rate of 24.9% per year. EQL Pharma's return on equity is 14%, and it has net margins of 9%.
Belangrijke informatie
35.3%
Groei van de winst
35.8%
Groei van de winst per aandeel
Healthcare Groei van de industrie | 8.1% |
Inkomstengroei | 24.9% |
Rendement op eigen vermogen | 14.0% |
Nettomarge | 9.0% |
Volgende winstupdate | 06 Nov 2024 |
Recente prestatie-updates uit het verleden
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings
Aug 22EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 21Recent updates
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher
Oct 29EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings
Aug 22Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden
Aug 12EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce
Jun 13EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price
May 14EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 21The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested
Jun 28With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case
Apr 28EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors
Feb 24EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital
Dec 19Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?
Jun 29Is EQL Pharma (NGM:EQL) Using Too Much Debt?
Apr 29We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair
Aug 10EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns
Jun 07If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late
Apr 16How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?
Mar 11Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 21Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 03What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation
Jan 16Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?
Dec 28What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?
Dec 11EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment
Nov 22Opbrengsten en kosten
Hoe EQL Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 291 | 26 | 74 | 13 |
31 Mar 24 | 264 | 23 | 71 | 12 |
31 Dec 23 | 246 | 22 | 68 | 14 |
30 Sep 23 | 256 | 28 | 64 | 14 |
30 Jun 23 | 270 | 30 | 63 | 14 |
31 Mar 23 | 260 | 31 | 60 | 15 |
31 Dec 22 | 403 | 33 | 59 | 14 |
30 Sep 22 | 440 | 39 | 56 | 11 |
30 Jun 22 | 419 | 36 | 51 | 9 |
31 Mar 22 | 410 | 32 | 48 | 9 |
31 Dec 21 | 233 | 19 | 41 | 10 |
30 Sep 21 | 145 | 4 | 34 | 11 |
30 Jun 21 | 117 | 2 | 31 | 12 |
31 Mar 21 | 179 | 10 | 28 | 12 |
31 Dec 20 | 172 | 17 | 32 | 2 |
30 Sep 20 | 163 | 16 | 32 | 2 |
30 Jun 20 | 157 | 14 | 32 | 2 |
31 Mar 20 | 72 | 3 | 30 | 0 |
31 Dec 19 | 68 | 2 | 24 | 5 |
30 Sep 19 | 58 | -2 | 25 | 3 |
30 Jun 19 | 54 | -2 | 25 | 2 |
31 Mar 19 | 50 | -2 | 25 | 0 |
31 Dec 18 | 43 | -2 | 21 | 0 |
30 Sep 18 | 41 | 0 | 20 | 0 |
30 Jun 18 | 35 | 0 | 18 | 0 |
31 Mar 18 | 32 | -1 | 17 | 0 |
31 Dec 17 | 30 | 1 | 16 | 0 |
30 Sep 17 | 30 | 0 | 15 | 0 |
30 Jun 17 | 26 | 0 | 15 | 0 |
31 Mar 17 | 24 | 0 | 14 | 0 |
31 Dec 16 | 31 | 4 | 15 | 0 |
30 Sep 16 | 29 | 5 | 14 | 0 |
30 Jun 16 | 34 | 6 | 14 | 0 |
31 Mar 16 | 35 | 7 | 14 | 0 |
31 Dec 15 | 29 | 4 | 13 | 0 |
30 Sep 15 | 26 | 1 | 13 | 0 |
30 Jun 15 | 21 | -2 | 13 | 0 |
31 Mar 15 | 19 | -5 | 13 | 0 |
31 Dec 14 | 18 | -9 | 13 | 0 |
30 Sep 14 | 19 | -11 | 13 | 0 |
30 Jun 14 | 19 | -12 | 12 | 0 |
31 Mar 14 | 20 | -11 | 11 | 0 |
31 Dec 13 | 22 | -8 | 10 | 0 |
Kwaliteitswinsten: EQL has a high level of non-cash earnings.
Groeiende winstmarge: EQL's current net profit margins (9%) are lower than last year (11.2%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: EQL has become profitable over the past 5 years, growing earnings by 35.3% per year.
Versnelling van de groei: EQL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: EQL had negative earnings growth (-13.4%) over the past year, making it difficult to compare to the Healthcare industry average (16.3%).
Rendement op eigen vermogen
Hoge ROE: EQL's Return on Equity (14%) is considered low.